1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator is a flagship initiative of the European Innovation Council (EIC) aimed at supporting innovative small and medium-sized enterprises (SMEs) and startups, particularly those working in deep technology sectors. Launched under the Horizon Europe framework, the EIC Accelerator provides funding and support for high-risk, high-potential innovations that can drive economic growth, job creation, and global competitiveness within the European Union.

Funding Structure

The EIC Accelerator offers a unique combination of grants and equity investments:

Purpose in the European DeepTech and Startup Ecosystem

The EIC Accelerator's primary objective is to foster innovation and entrepreneurship within Europe, particularly in the DeepTech domain, where complex scientific and engineering challenges are addressed through technological advancements. By providing financial resources and support:

• It reduces the risk associated with developing novel solutions.
• It helps bridge the gap between research and commercialization.
• It encourages collaboration between public and private sectors, enhancing the overall innovation ecosystem in Europe.

Role in Helping Companies Scale

The EIC Accelerator plays a crucial role in helping companies scale by:

• Providing Funding: The combination of grants and equity investments allows startups to secure the necessary capital for growth without immediately sacrificing equity or taking on debt.
• Business Development Support: Recipients gain access to a network of business coaches, mentors, and industry experts who guide them in refining their business models, scaling operations, and navigating challenges.
• Facilitating Private Investment: By demonstrating the viability and potential of their innovations through initial funding, companies can attract further investments from private equity firms, venture capitalists, and angel investors.

EVerZom and the ACROBAT Project

Company Name: EVerZom
Project Acronym: ACROBAT
Description: Toward the democratization of extracellular vesicles-based therapies
Funding Type: Grant first
Website: everzom.com
Country: France
Date of EIC Accelerator Submission: June 16, 2021

Overview of EVerZom

EVerZom is a French biotech company specializing in the research and development of extracellular vesicles (EVs), which are nanoscale particles released by all living cells that play a critical role in intercellular communication. The company focuses on harnessing these vesicles for therapeutic applications, including cancer treatment and regenerative medicine.

Project ACROBAT

The ACROBAT project aims to democratize access to EV-based therapies, making them more available and affordable for a wider population. The project focuses on developing scalable production and purification processes for EVs, ensuring that these innovative therapies can be manufactured in sufficient quantities and quality for clinical applications.

Technology Basics and Background

Extracellular Vesicles (EVs) are membrane-bound particles released by cells into the extracellular environment. They are classified mainly into three categories: exosomes, microvesicles, and apoptotic bodies, differing in their size, composition, and release mechanisms.

Key Characteristics:

• Size: EVs range from 30 to 1000 nm, with exosomes being the smallest (30-150 nm).
• Composition: They contain proteins, lipids, RNA, and other biomolecules, serving as carriers of cellular information.
• Functions: EVs play a pivotal role in various biological processes, including immune response modulation, tumor progression, and tissue repair.

Applications in Therapy:

Conclusion

The EIC Accelerator program significantly contributes to the maturation of the European startup ecosystem, particularly in deep technology fields. By supporting innovative companies like EVerZom with the ACROBAT project, it not only fuels technological advancements but also enhances the potential for groundbreaking therapies to reach the market, ultimately benefiting society as a whole.

2 The Funding Rounds

Since receiving the EIC Accelerator funding on June 16, 2021, EVerZom, a French biopharmaceutical company specializing in exosome bioproduction, has secured additional funding to advance its operations.

Funding Rounds:

Investor Information:

• EIC Accelerator Grant (June 16, 2021): As a grant, this funding did not involve equity investment or specific investor participation.
• Seed Funding Round (December 1, 2020): The funding was provided by a combination of institutional and private investors, including:
• Bpifrance, contributing up to €500,000 via the French Tech Seed fund.
• The Île-de-France region, with €300,000 via the Innov'up Leader Pia device.
• A group of private business angels, contributing €323,000. (nordic9.com)

Company Valuations:

Specific valuations for EVerZom during these funding rounds are not publicly disclosed. However, according to PitchBook, the company has raised a total of $4.13 million across various funding events, including grants and seed funding. (parsers.vc)

Additional Information:

EVerZom's proprietary technology involves applying mechanical stimulation to cells to trigger massive extracellular vesicle release, enabling the production of ten times more exosomes in ten times less time compared to classical methods. This innovation has attracted support from various European and U.S. biotech companies, particularly for vesicular treatments of digestive fistulas in patients with autoimmune diseases such as Crohn's disease or those who have undergone bariatric surgery. (businesswire.com)

As of now, there are no publicly available records of additional funding rounds or valuations beyond the mentioned events.

3 The Press Releases

Since receiving the EIC Accelerator funding on June 16, 2021, EVerZom, a French biopharmaceutical company specializing in exosome-based therapies, has made several significant advancements, as detailed in their press releases:

1. Exclusive License Agreement with Erganeo for EVerGel™

On March 5, 2024, EVerZom announced a second exclusive license agreement with Erganeo for the development of EVerGel™, their first drug candidate aimed at healing digestive tissues. EVerGel™ has demonstrated promising efficacy in eight animal models, leading to plans for regulatory preclinical studies by the end of 2024 and clinical trials in early 2026. (biospace.com)

2. Partnership with OmniSpirant for Lung Cancer Gene Therapy

On December 6, 2022, EVerZom and OmniSpirant Limited launched the INSPIRE project, a €12.8 million initiative funded by Horizon Europe. This collaboration aims to develop a regenerative gene therapy for lung cancer using extracellular vesicles. The project involves a consortium of European partners, including Aerogen Limited, Trinity College Dublin, RemedyBio, Myriad Associates, Biopharma Excellence (Pharmalex), Deutsches Krebsforschungszentrum (DKFZ), and Lung Cancer Europe. (businesswire.com)

3. Exclusive Distributorship Agreement with Summit Pharmaceuticals International (SPI)

On June 2, 2023, EVerZom signed an exclusive distributorship agreement with SPI, a Japanese company, to provide exosome manufacturing services in Japan. This partnership aims to support the research and development of exosomes, focusing on exosome manufacturing, engineering, quality control, and regulatory advice. (businesswire.com)

4. Achievement in Bioproduction of Clinical-Grade Exosomes

On October 2, 2024, EVerZom achieved a significant milestone by producing the first clinical-grade stem cell-derived exosomes in large-scale bioreactors, in partnership with the French Blood Establishment (EFS). This proprietary technology offers yields 100 times higher than traditional methods and has been validated in a GMP-grade biomanufacturing environment. The first clinical batch will enable EVerZom to initiate regulatory non-clinical studies of its first drug candidate, EVerGel™. (globenewswire.com)

5. Presentation of Exosome Biotherapies Pipeline

On December 13, 2023, EVerZom unveiled its proprietary pipeline of exosome-based biotherapies. The company aims to accelerate the clinical application of this novel therapeutic approach in various indications with critical medical needs, with its most advanced drug candidate targeting digestive tissue healing. (streetinsider.com)

These developments highlight EVerZom's commitment to advancing exosome-based therapies through strategic partnerships, technological innovations, and a robust pipeline of drug candidates.

4 The Technology Advancements

EVerZom, a biopharmaceutical company based in France, specializes in the biomanufacturing of exosomes—extracellular vesicles that facilitate intercellular communication and hold promise for regenerative medicine. Since receiving the EIC Accelerator funding on June 16, 2021, EVerZom has made significant advancements in its technology, partnerships, and therapeutic developments.

Technological Advancements and New Features:

• Enhanced Bioproduction Capabilities: In October 2024, EVerZom achieved a milestone by producing a clinical-grade batch of stem cell-derived exosomes in a 10L bioreactor, yielding 100 times more exosomes than traditional methods. This production was validated in collaboration with the French Blood Establishment (EFS) in Créteil, France. (globenewswire.com)
• Exclusive Licensing Agreement: In March 2024, EVerZom secured an exclusive licensing agreement with Erganeo for its first drug candidate, EVerGel. This agreement aims to advance the development of EVerGel, a treatment targeting digestive tissue healing, including conditions like fistulas and fibrosis. (globenewswire.com)

Market Demonstrations and Collaborations:

• INSPIRE Project for Lung Cancer Treatment: In December 2022, EVerZom partnered with OmniSpirant Limited to launch the INSPIRE project, a €12.8 million initiative funded by Horizon Europe. The project focuses on developing a regenerative gene therapy for lung cancer using extracellular vesicles. (businesswire.com)
• Exclusive Distribution Agreement in Japan: In June 2023, EVerZom signed an exclusive distributorship agreement with Summit Pharmaceuticals International (SPI) to expand its exosome production services in the Japanese market. This partnership aims to support exosome research and development in Japan. (businesswire.com)

Intellectual Property and Scientific Publications:

• Licensing Agreement with Erganeo: The licensing agreement with Erganeo not only advances EVerGel but also highlights the intellectual property rights EVerZom holds over its innovative exosome bioproduction technology. (erganeo.com)
• Scientific Resources: EVerZom has published scientific resources on topics such as exosome immunogenicity, stability, storage, and optimal cell sourcing for exosome production. These publications contribute to the broader scientific understanding of exosome-based therapies.

Through these advancements, EVerZom continues to position itself as a leader in exosome-based biotherapies, aiming to revolutionize regenerative medicine with innovative treatments for various medical conditions.

5 The Partnerships and Customers

EVerZom, a biopharmaceutical company specializing in exosome-based therapies, has established several strategic partnerships and collaborations to advance its mission in regenerative medicine.

Partnerships and Collaborations:

• Erganeo: In March 2024, EVerZom secured an exclusive license agreement with Erganeo for the development of EVerGel™, its first drug candidate aimed at treating fistulas and fibrosis of the digestive tract. This partnership signifies a significant step in EVerZom's commitment to delivering innovative exosome-based therapeutic solutions to patients with serious digestive diseases. (globenewswire.com)
• French Blood Establishment (EFS): In October 2024, EVerZom achieved a milestone by producing its first clinical-grade stem cell-derived exosomes in large-scale bioreactors, in partnership with the EFS. This collaboration resulted in unprecedented yields, facilitating the initiation of regulatory non-clinical studies for EVerGel™. (globenewswire.com)
• Omnispirant: EVerZom has partnered with Omnispirant for a therapeutic project in lung cancer, as part of the Horizon Europe Research and Innovation Actions (RIA) program. This collaboration aims to develop exosome-based therapies for lung cancer, leveraging EVerZom's proprietary technology platform. (globenewswire.com)

Nature and Purpose of Relationships:

• Erganeo: The exclusive license agreement with Erganeo is designed to advance the development of EVerGel™, focusing on the healing of digestive tissues. This partnership combines EVerZom's exosome technology with Erganeo's expertise in technology transfer to accelerate the clinical application of EVerGel™. (globenewswire.com)
• French Blood Establishment (EFS): The collaboration with EFS centers on the bioproduction of clinical-grade exosomes using large-scale bioreactors. This partnership aims to enhance the scalability and reproducibility of exosome production, ensuring a robust supply for clinical trials and potential commercialization. (globenewswire.com)
• Omnispirant: The partnership with Omnispirant focuses on developing exosome-based therapies for lung cancer, leveraging EVerZom's innovative platform to address unmet medical needs in oncology. (globenewswire.com)

Market Positioning and Technological Advancements:

These strategic partnerships position EVerZom at the forefront of exosome-based regenerative medicine, enhancing its market presence and technological capabilities. The collaboration with Erganeo and EFS strengthens EVerZom's ability to produce and develop exosome-based therapies efficiently, while the partnership with Omnispirant expands its therapeutic pipeline into oncology. Collectively, these relationships support EVerZom's mission to deliver innovative, off-the-shelf exosome-based treatments to patients worldwide.

6 The Hiring and Company Growth

EVerZom, a French biopharmaceutical company specializing in the biomanufacturing of exosomes, received €2.5 million in non-dilutive funding from the European Innovation Council (EIC) Accelerator on June 16, 2021. (businesswire.com) This funding aimed to support the transfer of their extracellular vesicle biomanufacturing technology for clinical-grade production and to accelerate the scale-up of their production capabilities for Phase 2/3 clinical trials.

Current Team Size and Hiring Status:

As of April 2025, specific details regarding EVerZom's current headcount and team size are not publicly disclosed. The company has not publicly announced any recent hiring initiatives or key positions filled. Additionally, there is no publicly available information about major changes in management or the founding team since the EIC Accelerator funding.

Growth and Future Outlook:

Since receiving the EIC Accelerator funding, EVerZom has focused on advancing its proprietary exosome biomanufacturing platform. In December 2023, the company unveiled its pipeline of exosome-based biotherapies, including EVergel, designed to improve the healing of digestive tissues, particularly targeting fistulas induced by Crohn's disease and healing of surgical anastomoses following tumor resection of the digestive tract. The development of EVergel is being conducted in collaboration with Prof. Gabriel Rahmi, a hepato-gastroenterologist at the Hôpital Européen Georges Pompidou in Paris, and Amanda Silva Brun, a researcher at the Matière et systèmes complexes laboratory at the Université Paris Cité. (tmcnet.com)

EVerZom's ambition to become a leader in exosome biotherapies is supported by its innovative platform, which covers the entire technological value chain from cell sourcing to exosome generation, engineering, and formulation. The company's focus on developing proprietary drug candidates in regenerative medicine, while establishing co-development partnerships in other therapeutic areas, positions it for future growth and scalability.

While specific details about team expansion and management changes are not publicly available, EVerZom's strategic initiatives and collaborations suggest a commitment to scaling its operations and advancing its therapeutic programs.

7 The Media Features and Publications

Since EVerZom received the EIC Accelerator funding on June 16, 2021, the company has been featured in various media outlets, publications, and events. Below is a summary of these engagements:

Media Features:

• Business Wire: On November 18, 2021, EVerZom announced its €2.5 million funding from the European EIC Accelerator program, highlighting its advancements in exosome bioproduction for regenerative medicine. (businesswire.com)
• GlobeNewswire: On December 13, 2023, EVerZom unveiled its proprietary pipeline of exosome-based biotherapies, emphasizing its commitment to accelerating clinical applications in regenerative medicine. (globenewswire.com)
• BioInformant: On November 18, 2021, BioInformant covered EVerZom's achievement in securing €2.5 million from the EIC Accelerator, focusing on the company's innovative approach to exosome biomanufacturing. (bioinformant.com)
• BioSpace: On November 18, 2021, BioSpace reported on EVerZom's €2.5 million funding from the EIC Accelerator, detailing the company's plans to scale up its exosome production capabilities. (biospace.com)
• GlobeNewswire: On October 2, 2024, EVerZom announced the successful bioproduction of clinical-grade stem cell-derived exosomes in large-scale bioreactors, achieved in partnership with the French Blood Establishment (EFS). (globenewswire.com)
• Manufacturing Chemist: On December 1, 2020, the publication highlighted EVerZom's €1.1 million funding to develop its exosome bioproduction platform, aiming for routine clinical-grade production by 2022. (manufacturingchemist.com)

Publications:

The following publications have featured EVerZom since June 16, 2021:

• Business Wire: Announced EVerZom's €2.5 million funding from the EIC Accelerator program on November 18, 2021. (businesswire.com)
• GlobeNewswire: Covered EVerZom's unveiling of its exosome-based biotherapies pipeline on December 13, 2023. (globenewswire.com)
• BioInformant: Reported on EVerZom's €2.5 million funding from the EIC Accelerator on November 18, 2021. (bioinformant.com)
• BioSpace: Highlighted EVerZom's plans to scale up exosome production following its €2.5 million funding on November 18, 2021. (biospace.com)
• GlobeNewswire: Announced EVerZom's successful bioproduction of clinical-grade exosomes in partnership with EFS on October 2, 2024. (globenewswire.com)
• Manufacturing Chemist: Discussed EVerZom's €1.1 million funding to develop its exosome bioproduction platform on December 1, 2020. (manufacturingchemist.com)

Podcasts or Interviews:

Specific details about podcasts or interviews featuring EVerZom's team since June 16, 2021, are not readily available in the provided sources.

Conference and Fair Visits, Presentations, or Participations:

Information regarding EVerZom's participation in conferences, fairs, or presentations since June 16, 2021, is not explicitly detailed in the available sources.

Involvement in Events:

Specific details about EVerZom's involvement in events since June 16, 2021, are not readily available in the provided sources.

For the most current and detailed information, it is recommended to visit EVerZom's official website or contact the company directly.